These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 17445886)

  • 1. Downregulation of c-Myc is critical for valproic acid-induced growth arrest and myeloid differentiation of acute myeloid leukemia.
    Cheng YC; Lin H; Huang MJ; Chow JM; Lin S; Liu HE
    Leuk Res; 2007 Oct; 31(10):1403-11. PubMed ID: 17445886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Programmed cell death-4 tumor suppressor protein contributes to retinoic acid-induced terminal granulocytic differentiation of human myeloid leukemia cells.
    Ozpolat B; Akar U; Steiner M; Zorrilla-Calancha I; Tirado-Gomez M; Colburn N; Danilenko M; Kornblau S; Berestein GL
    Mol Cancer Res; 2007 Jan; 5(1):95-108. PubMed ID: 17259349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia.
    Huang MJ; Cheng YC; Liu CR; Lin S; Liu HE
    Exp Hematol; 2006 Nov; 34(11):1480-9. PubMed ID: 17046567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor.
    Neri P; Tagliaferri P; Di Martino MT; Calimeri T; Amodio N; Bulotta A; Ventura M; Eramo PO; Viscomi C; Arbitrio M; Rossi M; Caraglia M; Munshi NC; Anderson KC; Tassone P
    Br J Haematol; 2008 Nov; 143(4):520-31. PubMed ID: 18986388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Downregulation of c-Myc determines sensitivity to 2-methoxyestradiol-induced apoptosis in human acute myeloid leukemia.
    Chow JM; Liu CR; Lin CP; Lee CN; Cheng YC; Lin S; Liu HE
    Exp Hematol; 2008 Feb; 36(2):140-8. PubMed ID: 18206725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-leukemic activity of valproic acid and imatinib mesylate on human Ph+ ALL and CML cells in vitro.
    Kircher B; Schumacher P; Petzer A; Hoflehner E; Haun M; Wolf AM; Nachbaur D; Gastl G
    Eur J Haematol; 2009 Jul; 83(1):48-56. PubMed ID: 19226363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acyclic retinoid synergises with valproic acid to inhibit growth in human hepatocellular carcinoma cells.
    Tatebe H; Shimizu M; Shirakami Y; Sakai H; Yasuda Y; Tsurumi H; Moriwaki H
    Cancer Lett; 2009 Nov; 285(2):210-7. PubMed ID: 19520494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HI44a, an anti-CD44 monoclonal antibody, induces differentiation and apoptosis of human acute myeloid leukemia cells.
    Song G; Liao X; Zhou L; Wu L; Feng Y; Han ZC
    Leuk Res; 2004 Oct; 28(10):1089-96. PubMed ID: 15289023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic administration of valproic acid inhibits PC3 cell growth by suppressing tumor angiogenesis in vivo.
    Gao D; Xia Q; Lv J; Zhang H
    Int J Urol; 2007 Sep; 14(9):838-45. PubMed ID: 17760752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Valproic acid for the treatment of myeloid malignancies.
    Kuendgen A; Gattermann N
    Cancer; 2007 Sep; 110(5):943-54. PubMed ID: 17647267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of differentiation and suppression of malignant phenotype of human neuroblastoma BE(2)-C cells by valproic acid: enhancement by combination with interferon-alpha.
    Cinatl J; Kotchetkov R; Blaheta R; Driever PH; Vogel JU; Cinatl J
    Int J Oncol; 2002 Jan; 20(1):97-106. PubMed ID: 11743648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Valproic acid sensitizes K562 erythroleukemia cells to TRAIL/Apo2L-induced apoptosis.
    Iacomino G; Medici MC; Russo GL
    Anticancer Res; 2008; 28(2A):855-64. PubMed ID: 18507029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the histone deacetylase inhibitor valproic acid on the sensitivity of anaplastic thyroid cancer cell lines to imatinib.
    Catalano MG; Pugliese M; Poli R; Bosco O; Bertieri R; Fortunati N; Boccuzzi G
    Oncol Rep; 2009 Feb; 21(2):515-21. PubMed ID: 19148530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects of sodium valproate on proliferation and apoptosis of human myelodysplastic syndromes cell line MUTZ-1].
    Chen BA; Zhao HH; Gao C; Shao ZY; Xia GH; Dohner K
    Ai Zheng; 2007 Dec; 26(12):1323-9. PubMed ID: 18076794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple Molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo.
    Shabbeer S; Kortenhorst MS; Kachhap S; Galloway N; Rodriguez R; Carducci MA
    Prostate; 2007 Jul; 67(10):1099-110. PubMed ID: 17477369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydroxyurea upregulates NKG2D ligand expression in myeloid leukemia cells synergistically with valproic acid and potentially enhances susceptibility of leukemic cells to natural killer cell-mediated cytolysis.
    Lu X; Ohata K; Kondo Y; Espinoza JL; Qi Z; Nakao S
    Cancer Sci; 2010 Mar; 101(3):609-15. PubMed ID: 20028385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NDRG1/2 expression is inhibited in primary acute myeloid leukemia.
    Tschan MP; Shan D; Laedrach J; Eyholzer M; Leibundgut EO; Baerlocher GM; Tobler A; Stroka D; Fey MF
    Leuk Res; 2010 Mar; 34(3):393-8. PubMed ID: 19775754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia.
    Cimino G; Lo-Coco F; Fenu S; Travaglini L; Finolezzi E; Mancini M; Nanni M; Careddu A; Fazi F; Padula F; Fiorini R; Spiriti MA; Petti MC; Venditti A; Amadori S; Mandelli F; Pelicci PG; Nervi C
    Cancer Res; 2006 Sep; 66(17):8903-11. PubMed ID: 16951208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel valproic acid derivatives with potent differentiation-inducing activity in myeloid leukemia cells.
    Deubzer H; Busche B; Rönndahl G; Eikel D; Michaelis M; Cinatl J; Schulze S; Nau H; Witt O
    Leuk Res; 2006 Sep; 30(9):1167-75. PubMed ID: 16510182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma.
    Kaiser M; Zavrski I; Sterz J; Jakob C; Fleissner C; Kloetzel PM; Sezer O; Heider U
    Haematologica; 2006 Feb; 91(2):248-51. PubMed ID: 16461312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.